Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
Fourth Quarter and Fiscal Year 2023 Summary & Recent Progress:
- Company continues to execute against Transformational Plan and achieved primary objective of reducing cash burn by over 50% vs. prior year
- Cash used in operations for fiscal year 2023 of
$12.9 million , down 52% year-over-year, from$27.0 million in the prior year period - Cash system revenue for fiscal year 2023 represented approximately 67% of total systems and subscriptions revenue, compared to 58% in the prior year period
- Cash used in operations for fiscal year 2023 of
- Macroeconomic headwinds and accelerated restructuring in international markets resulted in softer-than-expected system sales; total revenue of
$18.1 million , down$6.2 million , or 25%, year-over-year; up$0.5 million , or 3%, quarter-over-quarter - Operating expenses of
$19.7 million , including approximately$0.3 million of costs related to restructuring activities, down$5.0 million , or 20%, year-over-year - GAAP net loss attributable to stockholders of
$11.1 million , up$1.2 million , or 12% year-over-year - Adjusted EBITDA loss of
$5.9 million , down$0.4 million , or 7% year-over-year - On
October 5, 2023 , the Company announced that it finalized an agreement with its lenders to restructure its existing debt obligations, improving the Company's overall financial position by deferring certain principal and interest payments under its senior debt and exchanging a portion of its convertible notes for preferred stock. - On
October 17, 2023 , the Company announced a company-wide rebranding initiative, introducing Venus Aesthetic Intelligence (or "Venus AI") to reflect the new strategic vision for the Company and an enhanced focus on emerging technologies in aesthetics. - On
November 1, 2023 , the Company announced the commercial launch of its new multi-application platformVenus Versa Pro inthe United States . - On
January 24, 2024 , the Company announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value. As part of the process, the Board is considering a full range of strategic alternatives, which may include one or more financings, mergers, reverse mergers, other business combinations, sales of assets, licensing or other transactions. - On
March 25, 2024 , announced that it received a decision from theNasdaq Hearings Panel granting its request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(b) on or beforeMay 28, 2024 , and certain other conditions.
Management Commentary:
“Our fourth quarter revenue results reflect softer-than-expected system sales in the
Fourth Quarter and Twelve Months of 2023 Revenue by Region and by Product Type: |
||||||||||||||||
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
(dollars in thousands) | (dollars in thousands) | |||||||||||||||
Revenues by region: | ||||||||||||||||
$ | 11,789 | $ | 13,782 | $ | 43,454 | $ | 52,101 | |||||||||
International | 6,343 | 10,504 | 32,900 | 47,396 | ||||||||||||
Total revenue | $ | 18,132 | $ | 24,286 | $ | 76,354 | $ | 99,497 |
|
Three Months Ended |
Twelve Months Ended |
||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
(dollars in thousands) | (dollars in thousands) | |||||||||||||||
Revenues by product: | ||||||||||||||||
Subscription—Systems | $ | 6,064 | $ | 5,777 | $ | 20,504 | $ | 35,267 | ||||||||
Products—Systems | 8,662 | 14,068 | 41,874 | 47,906 | ||||||||||||
Products—Other (1) | 2,544 | 3,614 | 10,563 | 13,316 | ||||||||||||
Services | 862 | 827 | 3,413 | 3,008 | ||||||||||||
Total revenue | $ | 18,132 | $ | 24,286 | $ | 76,354 | $ | 99,497 |
(1) Products-Other include ARTAS procedure kits, Viva tips, Glide and other consumables. |
Fourth Quarter 2023 Financial Results: |
||||||||||||||||||||||||||
Three Months Ended |
||||||||||||||||||||||||||
2023 | 2022 | Change | ||||||||||||||||||||||||
(in thousands, except percentages) | $ | % of Total | $ | % of Total | $ | % | ||||||||||||||||||||
Revenues: | ||||||||||||||||||||||||||
Subscription—Systems | $ | 6,064 | 33.4 | $ | 5,777 | 23.8 | $ | 287 | 5.0 | |||||||||||||||||
Products—Systems | 8,662 | 47.8 | 14,068 | 57.9 | (5,406 | ) | (38.4 | ) | ||||||||||||||||||
Products—Other | 2,544 | 14.0 | 3,614 | 14.9 | (1,070 | ) | (29.6 | ) | ||||||||||||||||||
Services | 862 | 4.8 | 827 | 3.4 | 35 | 4.2 | ||||||||||||||||||||
Total | $ | 18,132 | 100.0 | $ | 24,286 | 100.0 | $ | (6,154 | ) | (25.3 | ) |
Total revenue for the fourth quarter of 2023 decreased
Gross profit for the fourth quarter of 2023 decreased
Operating expenses for the fourth quarter of 2023 decreased
Operating loss for the fourth quarter of 2023 was
Net loss attributable to stockholders for the fourth quarter of 2023 was
As of
Fiscal Year 2023 Financial Results: |
||||||||||||||||||||||||||
Twelve Months Ended |
||||||||||||||||||||||||||
2023 | 2022 | Change | ||||||||||||||||||||||||
(in thousands, except percentages) | $ | % of Total |
$ | % of Total |
$ | % | ||||||||||||||||||||
Revenues: | ||||||||||||||||||||||||||
Subscription—Systems | $ | 20,504 | 26.9 | $ | 35,267 | 35.5 | $ | (14,763 | ) | (41.9 | ) | |||||||||||||||
Products—Systems | 41,874 | 54.8 | 47,906 | 48.1 | (6,032 | ) | (12.6 | ) | ||||||||||||||||||
Products—Other | 10,563 | 13.8 | 13,316 | 13.4 | (2,753 | ) | (20.7 | ) | ||||||||||||||||||
Services | 3,413 | 4.5 | 3,008 | 3.0 | 405 | 13.5 | ||||||||||||||||||||
Total | $ | 76,354 | 100.0 | $ | 99,497 | 100.0 | $ | (23,143 | ) | (23.3 | ) |
Total revenue decreased by
Net loss attributable to stockholders for the twelve months ended
Fiscal Year 2024 Financial Outlook:
Given the Company’s active dialogue with existing lenders and investors and the ongoing evaluation of strategic alternatives with various interested parties to maximize shareholder value, the Company is not providing full year 2024 financial guidance at this time. The Company expects total revenue for the three months ending
Conference Call Details:
Management will host a conference call at
For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13744647.
About
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, but are not limited to, statements about our financial performance and metrics; the growth in demand for our systems and other products; the efficacy of the Venus Versa Pro; the contribution of the Venus Versa Pro to our revenue; the efficacy of the restructuring plan; the identification and efficacy of strategic alternatives to maximize shareholder value; the reduction in our cash burn; and our ability to regain compliance with the continued listing rules of the Nasdaq Capital Market. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended
Condensed Consolidated Balance Sheets (In thousands of |
||||||||
Year Ended, |
||||||||
2023 | 2022 | |||||||
ASSETS | ||||||||
CURRENT ASSETS: | ||||||||
Cash and cash equivalents | $ | 5,396 | $ | 11,569 | ||||
Accounts receivable, net of allowance of |
29,151 | 37,262 | ||||||
Inventories | 23,072 | 23,906 | ||||||
Prepaid expenses | 1,298 | 1,688 | ||||||
Advances to suppliers | 5,604 | 5,881 | ||||||
Other current assets | 1,925 | 3,702 | ||||||
Total current assets | 66,446 | 84,008 | ||||||
LONG-TERM ASSETS: | ||||||||
Long-term receivables, net | 11,318 | 20,044 | ||||||
Deferred tax assets | 1,032 | 947 | ||||||
Severance pay funds | 573 | 741 | ||||||
Property and equipment, net | 1,322 | 1,857 | ||||||
Operating right-of-use assets, net | 4,517 | 5,862 | ||||||
Intangible assets | 8,446 | 11,919 | ||||||
Total long-term assets | 27,208 | 41,370 | ||||||
TOTAL ASSETS | $ | 93,654 | $ | 125,378 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
CURRENT LIABILITIES: | ||||||||
Trade payables | $ | 9,038 | $ | 8,033 | ||||
Accrued expenses and other current liabilities | 12,437 | 16,667 | ||||||
Current portion of long-term debt | 4,155 | 7,735 | ||||||
Income taxes payable | 366 | 117 | ||||||
Unearned interest income | 1,468 | 2,397 | ||||||
Warranty accrual | 1,029 | 1,074 | ||||||
Deferred revenues | 1,076 | 1,765 | ||||||
Operating lease liabilities | 1,590 | 1,807 | ||||||
Total current liabilities | 31,159 | 39,595 | ||||||
LONG-TERM LIABILITIES: | ||||||||
Long-term debt | 70,790 | 70,003 | ||||||
Income tax payable | — | 374 | ||||||
Accrued severance pay | 634 | 867 | ||||||
Deferred tax liabilities | 15 | — | ||||||
Unearned interest revenue | 671 | 957 | ||||||
Warranty accrual | 334 | 408 | ||||||
Operating lease liabilities | 3,162 | 4,221 | ||||||
Other long-term liabilities | 338 | 215 | ||||||
Total long-term liabilities | 75,944 | 77,045 | ||||||
TOTAL LIABILITIES | 107,103 | 116,640 | ||||||
Commitments and Contingencies (Note 9) | ||||||||
STOCKHOLDERS’ EQUITY (DEFICIT) (Note 14): | ||||||||
Common Stock, |
30 | 29 | ||||||
Additional paid-in capital | 247,854 | 232,169 | ||||||
Accumulated deficit | (261,903 | ) | (224,105 | ) | ||||
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | (14,019 | ) | 8,093 | |||||
Non-controlling interests | 570 | 645 | ||||||
(13,449 | ) | 8,738 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ | 93,654 | $ | 125,378 |
Condensed Consolidated Statements of Operations (In thousands of |
|||||||||||||||||||
Three Months Ended |
Twelve Months Ended |
||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||
Revenue | |||||||||||||||||||
Leases | $ | 6,064 | $ | 5,777 | $ | 20,504 | $ | 35,267 | |||||||||||
Products and services | 12,068 | 18,509 | 55,850 | 64,230 | |||||||||||||||
18,132 | 24,286 | 76,354 | 99,497 | ||||||||||||||||
Cost of goods sold: | |||||||||||||||||||
Leases | 679 | 1,366 | 4,312 | 9,435 | |||||||||||||||
Products and services | 5,390 | 7,131 | 19,875 | 24,091 | |||||||||||||||
6,069 | 8,497 | 24,187 | 33,526 | ||||||||||||||||
Gross profit | 12,063 | 15,879 | 52,167 | 65,971 | |||||||||||||||
Operating expenses: | |||||||||||||||||||
Selling and marketing | 7,912 | 9,300 | 31,213 | 40,276 | |||||||||||||||
General and administrative | 10,115 | 12,804 | 41,048 | 49,618 | |||||||||||||||
Research and development | 1,670 | 2,573 | 8,197 | 10,953 | |||||||||||||||
Total operating expenses | 19,697 | 24,678 | 80,476 | 100,847 | |||||||||||||||
Loss from operations | (7,634) | (8,889 | ) | (28,309 | ) | (34,876 | ) | ||||||||||||
Other expenses: | |||||||||||||||||||
Foreign exchange loss | (674 | ) | (1,002 | ) | (295 | ) | 3,387 | ||||||||||||
Finance expenses | 2,227 | 1,385 | 6,893 | 4,561 | |||||||||||||||
Loss on disposal of subsidiaries | 97 | 1,482 | 174 | 1,482 | |||||||||||||||
Loss on debt extinguishment | 2,040 | — | 2,040 | — | |||||||||||||||
Loss before income taxes | (11,324) | (10,754 | ) | (37,121 | ) | (44,306 | ) | ||||||||||||
Income tax (benefit) expense | (174) | (814 | ) | (71 | ) | (722 | ) | ||||||||||||
Net loss | (11,150) | (9,940 | ) | (37,050 | ) | (43,584 | ) | ||||||||||||
Net loss attributable to stockholders of the Company | (11,116) | (9,917 | ) | (37,250 | ) | (43,700 | ) | ||||||||||||
Net income attributable to non-controlling interest | (34) | (23 | ) | 200 | 116 | ||||||||||||||
Net loss per share: | |||||||||||||||||||
Basic | $ | (2.01) | $ | (2.11 | ) | $ | (6.84 | ) | $ | (9.94 | ) | ||||||||
Diluted | $ | (2.01) | $ | (2.11 | ) | $ | (6.84 | ) | $ | (9.94 | ) | ||||||||
Weighted-average number of shares used in per share calculation: | |||||||||||||||||||
Basic | 5,529 | 4,694 | 5,442 | 4,398 | |||||||||||||||
Diluted | 5,529 | 4,694 | 5,442 | 4,398 |
Condensed Consolidated Statements of Cash Flows (in thousands) |
||||||||
Year Ended |
||||||||
2023 | 2022 | |||||||
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES: | ||||||||
Net loss | $ | (37,050 | ) | $ | (43,584 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 4,115 | 4,463 | ||||||
Stock-based compensation | 1,569 | 2,104 | ||||||
Provision for bad debt | 1,350 | 7,337 | ||||||
Provision for inventory obsolescence | 1,158 | 2,420 | ||||||
Finance expenses and accretion | 2,206 | 414 | ||||||
Deferred tax recovery | (69 | ) | (709 | ) | ||||
Loss on sale of subsidiary | 174 | - | ||||||
Loss on disposal of property and equipment | 10 | 158 | ||||||
Loss on debt extinguishment | 2,040 | - | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable short- and long-term | 14,891 | 9,855 | ||||||
Inventories | (324 | ) | (5,783 | ) | ||||
Prepaid expenses | 390 | 1,049 | ||||||
Advances to suppliers | 277 | (214 | ) | |||||
Other current assets | 1,603 | 56 | ||||||
Operating right-of-use assets, net | 1,345 | (5,862 | ) | |||||
Other long-term assets | 47 | 200 | ||||||
Trade payables | 1,005 | (385 | ) | |||||
Accrued expenses and other current liabilities | (5,089 | ) | (3,647 | ) | ||||
Current operating lease liabilities | (217 | ) | 1,807 | |||||
Severance pay funds | 168 | 76 | ||||||
Unearned interest income | (1,215 | ) | (679 | ) | ||||
Long-term operating lease liabilities | (1,059 | ) | 4,221 | |||||
Other long-term liabilities | (184 | ) | (277 | ) | ||||
Net cash used in operating activities | (12,859 | ) | (26,980 | ) | ||||
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES: | ||||||||
Purchases of property and equipment | (116 | ) | (336 | ) | ||||
Net cash used in investing activities | (116 | ) | (336 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
2022 Private Placement, net of costs of |
- | 6,518 | ||||||
2023 Private Placement, net of costs of |
6,261 | - | ||||||
Proceeds from issuance of common stock | 816 | 2,135 | ||||||
Repayment of government assistance loans | - | (543 | ) | |||||
Dividends from subsidiaries paid to non-controlling interest | (275 | ) | (124 | ) | ||||
Proceeds from exercise of options | - | 23 | ||||||
Net cash provided by financing activities | 6,802 | 8,009 | ||||||
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (6,173 | ) | (19,307 | ) | ||||
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of year | 11,569 | 30,876 | ||||||
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of year | $ | 5,396 | $ | 11,569 | ||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
Cash paid for income taxes | $ | 124 | $ | 329 | ||||
Cash paid for interest | $ | 4,473 | $ | 4,147 |
Use of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP measure defined as net income (loss) before foreign exchange loss, financial expenses, income tax expense (benefit), depreciation and amortization, stock-based compensation and non-recurring items for a given period. Adjusted EBITDA is not a measure of our financial performance under
We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the
The following reconciliation of net (loss) income to Adjusted EBITDA for the periods presented:
Reconciliation of Net loss to Non-GAAP Adjusted EBITDA |
||||||||||||||||||||
Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||||||
Reconciliation of net loss to adjusted EBITDA | (in thousands) | (in thousands) | ||||||||||||||||||
Net loss | $ | (11,150 | ) | $ | (9,937 | ) | $ | (37,050 | ) | $ | (43,584 | ) | ||||||||
Foreign exchange loss | (674 | ) | (1,002 | ) | (295 | ) | 3,387 | |||||||||||||
Loss on disposal of subsidiaries | 97 | 1,482 | 174 | 1,482 | ||||||||||||||||
Loss on debt extinguishment | 2,040 | — | 2,040 | — | ||||||||||||||||
Finance expenses | 2,227 | 1,385 | 6,893 | 4,561 | ||||||||||||||||
Income tax (benefit) expense | (174 | ) | (814 | ) | (71 | ) | (722 | ) | ||||||||||||
Depreciation and amortization | 1,073 | 1,070 | 4,115 | 4,463 | ||||||||||||||||
Stock-based compensation expense | 355 | 552 | 1,569 | 2,104 | ||||||||||||||||
Inventory Provision (1) | — | — | — | 1,388 | ||||||||||||||||
Other adjustments (2) | 280 | 818 | 2,362 | 1,544 | ||||||||||||||||
Adjusted EBITDA | $ | (5,926 | ) | $ | (6,347 | ) | $ | (20,263 | ) | $ | (25,377 | ) |
(1) For the year ended
(2) For the year ended
Investor Relations Contact:ICR Westwicke on behalf ofVenus Concept :Mike Piccinino , CFA VenusConceptIR@westwicke.com
Source: Venus Concept Inc.